United Kingdom-based Oncimmune Holdings has signed an exclusive commercial collaboration with Russia-based R-Pharm JSC.
It was reported on Friday that the contract has been signed to use Oncimmune's EarlyCDT Lung for the early detection of lung cancer in Russia and the member states of the Eurasian Customs Union (Republic of Belarus, Kazakhstan, Armenia and Kyrgyzstan).
According to the terms of the contract, Oncimmune has granted an option to R-Pharm to extend the use of EarlyCDT Lung into the Commonwealth of Independent States countries of Azerbaijan, Turkmenistan, Tajikistan, Ukraine, Uzbekistan, and Georgia. The five-year initial term intends to generate revenues of around GBP5m, including milestone payments of GBP2.75m during this period. R-Pharm will commercialise EarlyCDT Lung in both lung cancer screening and nodule risk assessment in the region.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review